

MDK Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP7781a**Specification**

MDK Antibody (N-term) Blocking Peptide - Product Information

Primary Accession [P21741](#)
Other Accession [NP_002382](#)

MDK Antibody (N-term) Blocking Peptide - Additional Information

Gene ID 4192

Other Names

Midkine, MK, Amphiregulin-associated protein, ARAP, Midgestation and kidney protein, Neurite outgrowth-promoting factor 2, Neurite outgrowth-promoting protein, MDK, MK1, NRGF2

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP7781a](#) was selected from the N-term region of human MDK. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MDK Antibody (N-term) Blocking Peptide - Protein Information

Name MDK ([HGNC:6972](#))

Synonyms MK1, NRGF2

Function

Secreted protein that functions as a cytokine and growth factor and mediates its signal through cell-surface proteoglycan and non-proteoglycan receptors (PubMed: [10212223](#), PubMed: [10772929](#), PubMed: [12084985](#), PubMed: [12122009](#), PubMed: [12573468](#), PubMed: [15466886](#)).

href="http://www.uniprot.org/citations/18469519" target="_blank">18469519, PubMed:24458438). Binds cell-surface proteoglycan receptors via their chondroitin sulfate (CS) groups (PubMed:10212223, PubMed:12084985). Thereby regulates many processes like inflammatory response, cell proliferation, cell adhesion, cell growth, cell survival, tissue regeneration, cell differentiation and cell migration (PubMed:10212223, PubMed:10683378, PubMed:10772929, PubMed:12084985, PubMed:12122009, PubMed:12573468, PubMed:15466886, PubMed:22323540, PubMed:24458438). Participates in inflammatory processes by exerting two different activities. Firstly, mediates neutrophils and macrophages recruitment to the sites of inflammation both by direct action by cooperating namely with ITGB2 via LRP1 and by inducing chemokine expression (PubMed:10683378, PubMed:24458438). This inflammation can be accompanied by epithelial cell survival and smooth muscle cell migration after renal and vessel damage, respectively (PubMed:10683378). Secondly, suppresses the development of tolerogenic dendritic cells thereby inhibiting the differentiation of regulatory T cells and also promote T cell expansion through NFAT signaling and Th1 cell differentiation (PubMed:22323540). Promotes tissue regeneration after injury or trauma. After heart damage negatively regulates the recruitment of inflammatory cells and mediates cell survival through activation of anti-apoptotic signaling pathways via MAPKs and AKT pathways through the activation of angiogenesis (By similarity). Also facilitates liver regeneration as well as bone repair by recruiting macrophage at trauma site and by promoting cartilage development by facilitating chondrocyte differentiation (By similarity). Plays a role in brain by promoting neural precursor cells survival and growth through interaction with heparan sulfate proteoglycans (By similarity). Binds PTPRZ1 and promotes neuronal migration and embryonic neurons survival (PubMed:10212223). Binds SDC3 or GPC2 and mediates neurite outgrowth and cell adhesion (PubMed:12084985, PubMed:1768439). Binds chondroitin sulfate E and heparin leading to inhibition of neuronal cell adhesion induced by binding with GPC2 (PubMed:12084985). Binds CSPG5 and promotes elongation of oligodendroglial precursor-like cells (By similarity). Also binds ITGA6:ITGB1 complex; this interaction mediates MDK-induced neurite outgrowth (PubMed:15466886, PubMed:1768439). Binds LRP1; promotes neuronal survival (PubMed:10772929). Binds ITGA4:ITGB1 complex; this interaction mediates MDK-induced osteoblast cells migration through PXN phosphorylation (PubMed:15466886). Binds anaplastic lymphoma kinase (ALK) which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate (IRS1), followed by the activation of mitogen-activated protein kinase (MAPK) and PI3-kinase, and the induction of cell proliferation (PubMed:12122009). Promotes epithelial to mesenchymal transition through interaction with NOTCH2 (PubMed:18469519). During arteriogenesis, plays a role in vascular endothelial cell proliferation by inducing VEGFA expression and release which in turn induces nitric oxide synthase

expression. Moreover activates vasodilation through nitric oxide synthase activation (By similarity). Negatively regulates bone formation in response to mechanical load by inhibiting Wnt/beta- catenin signaling in osteoblasts (By similarity). In addition plays a role in hippocampal development, working memory, auditory response, early fetal adrenal gland development and the female reproductive system (By similarity).

Cellular Location

Secreted.

Tissue Location

Expressed in various tumor cell lines. In insulinoma tissue predominantly expressed in precancerous lesions

MDK Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

MDK Antibody (N-term) Blocking Peptide - Images**MDK Antibody (N-term) Blocking Peptide - Background**

MDK has heparin binding activity and growth promoting activity. It is involved in neointima formation after arterial injury, possibly by mediating leukocyte recruitment and also involved in early fetal adrenal gland development.

MDK Antibody (N-term) Blocking Peptide - References

Huang,Y., Biochem. Biophys. Res. Commun. 377 (2), 474-478 (2008)Ikematsu,S., Cancer Sci. 99 (10), 2070-2074 (2008)Ota,K., Br. J. Cancer 99 (4), 655-662 (2008)